PFIZER INC.
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A 6-week Study to Evaluate the Safety and Efficacy of Quillichew ERCT in 4-5 Year Old Children With ADHD.
- Conditions
- Attention Deficit Hyperactivity DisorderAttention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- Drug: PlaceboDrug: methylphenidate HCl ERCT
- First Posted Date
- 2018-07-09
- Last Posted Date
- 2018-11-01
- Lead Sponsor
- Pfizer
- Registration Number
- NCT03580005
Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria
- Conditions
- Serious Bacterial Infection
- Interventions
- Combination Product: ATM-AVIDrug: BAT
- First Posted Date
- 2018-07-09
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 15
- Registration Number
- NCT03580044
- Locations
- π¨π³
The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China
π¨π³Hunan Province People's Hospital, Changsha, Hunan, China
π¨π³The First Hospital of Kunming, Kunming, China
Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age
- Conditions
- Clostridium Difficile Associated Disease
- Interventions
- Biological: Clostridium difficile vaccineBiological: placebo
- First Posted Date
- 2018-07-06
- Last Posted Date
- 2023-01-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1317
- Registration Number
- NCT03579459
- Locations
- πΊπΈ
Amici Clinical Research, Raritan, New Jersey, United States
πΊπΈCoastal Clinical Research, Inc., Mobile, Alabama, United States
πΊπΈParadigm Clinical Research Centers, Inc., Redding, California, United States
Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis
- Conditions
- Dermatitis, Atopic
- Interventions
- First Posted Date
- 2018-07-03
- Last Posted Date
- 2020-04-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 391
- Registration Number
- NCT03575871
- Locations
- π¨π¦
Diex Recherche Sherbrooke Inc., Sherbrooke, Quebec, Canada
πΊπΈThe Ohio State University Wexner Medical Center, Columbus, Ohio, United States
πΊπΈCenter for Clinical Studies, LTD. LLP, Houston, Texas, United States
A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young Children
- Conditions
- Pneumococcal InfectionsPneumococcal Conjugate Vaccine
- Interventions
- Biological: 13vPnCBiological: Hib
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 936
- Registration Number
- NCT03574389
- Locations
- π¨π³
Huaiyin District Center for Disease Prevention and Control, Huaian, Jiangsu, China
π¨π³Guanyun County Disease Control and Prevention, Lianyungang, Jiangsu, China
Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031
- First Posted Date
- 2018-06-29
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 179
- Registration Number
- NCT03573882
- Locations
- πΊπΈ
Children's Healthcare of Atlanta at Hughes Spalding, Atlanta, Georgia, United States
πΊπΈUniversity of Illinois Hospital and Health Science System, Chicago, Illinois, United States
πΊπΈDana Farber Cancer Institute, Boston, Massachusetts, United States
Non-interventional, Retrospective Cohort Study to Explore OAC Treatment in Korea
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2018-06-28
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 64684
- Registration Number
- NCT03572972
- Locations
- π°π·
Korea University Hospital, Seoul, Korea, Republic of
A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults
- Conditions
- Respiratory Tract Infection
- Interventions
- Biological: Formulation ABiological: PlaceboBiological: Formulation BBiological: Formulation C
- First Posted Date
- 2018-06-28
- Last Posted Date
- 2021-08-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 317
- Registration Number
- NCT03572062
- Locations
- π¦πΊ
Doctors of Ivanhoe, Ivanhoe, Victoria, Australia
π¦πΊAustralian Clinical Research Network, Maroubra, New South Wales, Australia
π¦πΊHoldsworth House Medical Practice, Sydney, New South Wales, Australia
A Safety And Immunogenicity Study Of A 13-valent Pneumococcal Conjugate Vaccine In Japanese Subjects Aged 6 To 64 Years.
- Conditions
- Pneumococcal Infections
- Interventions
- Biological: 13-valent pneumococcal conjugate vaccine
- First Posted Date
- 2018-06-27
- Last Posted Date
- 2020-02-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 206
- Registration Number
- NCT03571607
- Locations
- π―π΅
National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan
π―π΅Nagano Prefectural Shinshu Medical Center, Suzaka, Nagano, Japan
π―π΅Kawasaki Municipal Hospital, Kawasaki, Kanagawa, Japan
Safety and Effectiveness of Oral Anticoagulants in Patients With Non-valvular Atrial Fibrillation
- Conditions
- Non-valvular Atrial Fibrillation
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 73989
- Registration Number
- NCT03570047
- Locations
- π―π΅
Pfizer Japan, Tokyo, Japan